Autobio(SH:603658) Xin Lang Cai Jing·2025-10-30 12:16Core Viewpoint - Antu Biology is a leading company in the in vitro diagnostics sector in China, with a comprehensive product range and strong market position, ranking second in revenue and third in net profit among industry peers in Q3 2025 [1][2]. Group 1: Business Performance - In Q3 2025, Antu Biology reported revenue of 3.127 billion yuan, ranking second among 39 companies in the industry, with the top company generating 3.428 billion yuan [2]. - The revenue composition includes 1.785 billion yuan from reagents (86.63%), 226 million yuan from instruments (10.99%), and 28.9 million yuan from other sources (1.40%) [2]. - The net profit for the same period was 873 million yuan, placing the company third in the industry, with the leading company achieving 1.588 billion yuan [2]. Group 2: Financial Ratios - As of Q3 2025, Antu Biology's debt-to-asset ratio was 24.57%, higher than the industry average of 18.29%, but down from 25.49% in the previous year [3]. - The gross profit margin stood at 64.83%, exceeding the industry average of 56.20%, although it slightly decreased from 65.86% year-on-year [3]. Group 3: Management and Shareholder Information - The chairman, Miao Yongjun, received a salary of 1.06 million yuan in both 2024 and 2023, indicating stability in compensation [4]. - As of September 30, 2025, the number of A-share shareholders decreased by 0.58% to 34,000, while the average number of shares held per shareholder increased by 0.58% to 16,800 [5]. Group 4: Market Outlook and Innovations - The company is actively expanding its overseas market presence, with overseas revenue reaching 157 million yuan in the first half of 2025, a year-on-year increase of 19.8% [5]. - Antu Biology plans to launch new products, including a liquid chromatography-tandem mass spectrometry series in 2025, and has made significant progress in the NGS sector through its subsidiary [6]. - The company is expected to see a gradual recovery in performance, with projected net profits of 1.108 billion yuan, 1.340 billion yuan, and 1.617 billion yuan for 2025, 2026, and 2027, respectively [6].